SEB Inv. Mgmt. AB v. Endo Int'l, PLC
351 F. Supp. 3d 874
E.D. Pa.2018Background
- Endo reformulated its opioid Opana ER and sought FDA abuse-deterrent labeling and a Citizen Petition to have the original formulation withdrawn for safety reasons; FDA denied abuse‑deterrent labeling in 2011 and again after post‑marketing reviews.
- Endo publicly touted post‑marketing surveillance (NAVIPPRO, RADARS, FAERS) as showing reduced abuse and likened Opana ER to reformulated OxyContin, while allegedly withholding adverse data showing a shift from intranasal to increased intravenous (injection) abuse and related serious events (e.g., TTP/TMA, HIV clusters).
- SEB Investment Management filed a putative securities class action under §10(b)/Rule 10b‑5 and §§11, 15 of the Securities Act, alleging material misstatements and omissions in public statements, SEC filings, and June 2015 offering materials; seeks Exchange Act and Securities Act relief.
- Defendants moved to dismiss arguing hindsight pleading, that challenged statements were opinions or forward‑looking statements protected by the PSLRA safe harbor, and that scienter was not adequately pleaded; they also invoked Colorado River abstention for Securities Act claims.
- The court denied the motion to dismiss as to Endo and certain individual defendants (De Silva, Levin, Gergel, McHugh, Blaine Davis) finding SEB adequately pled falsity, materiality, and a strong inference of scienter for those defendants; claims against Holveck, Matthew Davis, Hall, and Campanelli were dismissed.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Exchange Act statements and omissions about Opana ER's abuse‑deterrent properties were materially false or misleading | Endo touted reduced abuse and crush resistance while concealing post‑marketing data showing increased IV abuse and serious adverse events | Statements were opinions/optimistic forward‑looking comments or puffery and not false when made; later data cannot show prior falsity (hindsight) | Court: Sufficiently pled falsity for statements that touted reduced abuse while omitting contrary IV‑abuse data (esp. Nov 2012 and Mar 2013 filings) — denial of dismissal as to certain defendants |
| Whether challenged forward‑looking/opinion statements are protected by the PSLRA safe harbor | SEB: Safe harbor inapplicable where speakers failed to disclose known, contradictory data embedded in their optimistic statements | Defendants: Statements were forward‑looking or subjective opinions with cautionary language and thus protected | Court: Some statements were protected puffery; others (those that affirmatively asserted reduced abuse while concealing contrary data) are not protected because defendants omitted known, materially adverse facts |
| Whether scienter was adequately alleged for individual defendants | SEB: Executives had access to surveillance, REMS reviews, and other core data; Opana ER was a core revenue product creating motive; officers publicly vouched for the data while omitting adverse findings — supporting a strong inference of conscious recklessness | Defendants: No direct allegations of actual knowledge; inferences are circumstantial and insufficient; positions alone cannot establish scienter | Court: Considering positions, access, statements, and product importance, SEB pleaded a strong inference of recklessness/knowledge as to De Silva, Levin, Gergel, McHugh, and Blaine Davis; scienter not pled as to several other officers |
| Whether Securities Act claims (§11/§15) survive and whether federal abstention is warranted | SEB: June 2015 offering materials omitted material adverse information about IV abuse and regulatory risk, supporting §11 negligence claims and §15 control‑person claims; state suit is not parallel | Defendants: Colorado River abstention appropriate because similar claims exist in state court; offering materials were not misleading | Court: State action not sufficiently parallel; SEB pleaded material omissions in the registration/offering materials and control‑person liability — §11 and §15 claims survive against relevant defendants |
Key Cases Cited
- Williams v. Globus Med., Inc., 869 F.3d 235 (3d Cir.) (standards for Rule 12(b)(6) and securities pleading rigor)
- OFI Asset Mgmt. v. Cooper Tire & Rubber, 834 F.3d 481 (3d Cir.) (PSLRA and forward‑looking statement analysis)
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (U.S.) (standard for pleading scienter; "strong inference" test)
- Dura Pharm., Inc. v. Broudo, 544 U.S. 336 (U.S.) (loss causation/economic loss element)
- In re Merck & Co., Inc. Securities Litigation, 432 F.3d 261 (3d Cir.) (efficient market hypothesis and materiality measured by stock‑price reaction)
- Omnicare, Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 135 S. Ct. 1318 (U.S.) (when statements of opinion are actionable under §11)